Ask AI
PBC Response to First Line Therapy

CE / CME

Assessing PBC Response to First-line UDCA Therapy

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: March 18, 2026

Expiration: March 17, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871-7. 
  2. Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023;21:2076-2087.
  3. Harms MH, Lammers WJ, Thorburn D, et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am J Gastroenterol. 2018;113:254-264.
  4. Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394-419.
  5. Murillo Perez CF, Ioannou S, Hassanally I, et al. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival. Liver Int. 2023;43:1497-1506. 
  6. American Association for the Study of Liver Diseases. Primary biliary cholangitis. aasld.org/practice-guidelines/primary-biliary-cholangitis. Accessed March 13, 2026.
  7. Martins A, Levy C. The impact of deep response to ursodeoxycholic acid in primary biliary cholangitis - should it be the new clinical standard? Curr Opin Gastroenterol. 2025;41:74-80.
  8. Murillo Perez CF, Harms MH, Lindor KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115:1066-1074. 
  9. Corpechot C, Lemoinne S, Soret PA, et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. 2024;79:39-48.
  10. Kowdley KV, Bowlus CL, Levy C, et al. Application of the latest advances in evidence-based medicine in primary biliary cholangitis. Am J Gastroenterol. 2023;118:232-242.
  11. Osman KT, Maselli DB, Idilman IS, et al. Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis. J Clin Gastroenterol. 2021;55:449-457.